Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 301

Lumos Pharma Acquires Candidate for Oral Treatment of Growth Hormone Deficiency

Posted by fidest press agency su mercoledì, 26 settembre 2018

Lumos Pharma, Inc., a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases, today announced that it has acquired the license for LUM-201, an investigational orally administered small molecule that promotes secretion of growth hormone from the pituitary gland, from Ammonett Pharma LLC. Lumos plans to initiate a Phase IIb trial in 2019 in patients with Pediatric Growth Hormone Deficiency (PGHD) to compare multiple doses of LUM-201 to daily injections of recombinant human growth hormone, which is the current standard of care. Rick Hawkins, CEO of Lumos Pharma, commented, “The Lumos investors and the entire Lumos team are extremely excited for the opportunity to rapidly advance this oral candidate for PGHD patients. Many patients will potentially appreciate an alternative to injections.” Michael Thorner, MB, BS, DSc, a leading endocrinologist based at the University of Virginia and adviser to Lumos who has long been involved with the program while an executive at Ammonett Pharma, commented, “Lumos is the perfect company to advance this treatment to approval. It has excellent rare disease drug development expertise and resources. I look forward to working with the team on the product’s development and commercialization.”

Rispondi

Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo WordPress.com

Stai commentando usando il tuo account WordPress.com. Chiudi sessione /  Modifica )

Google photo

Stai commentando usando il tuo account Google. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

 
%d blogger hanno fatto clic su Mi Piace per questo: